Trial Profile

Intravitreal Brolucizumab in Neovascular Age-related Macular Degeneration With Limited Response to Aflibercept

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 30 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brolucizumab (Primary)
Indications Wet age-related macular degeneration
Focus Therapeutic Use
Acronyms ROBIN

Most Recent Events

08 Dec 2021 Status changed from recruiting to discontinued. Reason the study was stopped: due to safety letter beovu from Novartis
11 Aug 2020 Status changed from not yet recruiting to recruiting.
30 Mar 2020 Planned initiation date changed from 1 Feb 2020 to 1 Apr 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com